Analytical and clinical pharmacokinetic bridging studies between local and foreign versions of the same reference biologic are redundant, costly, scientifically unnecessary for biosimilar development and should be eliminated as a regulatory requirement, according to a recent journal article.
Christopher Webster and Gillian Woollett argue the case for adoption of a “global reference comparator,” whereby a single approved version...





